Navigation Links
Express Scripts Announces Intention to Commence a Debt Offering
Date:4/25/2011

/www.consumerology.com/.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements, including, but not limited to, statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. Actual results may differ significantly from those projected or suggested in any forward-looking statements.  Factors that may impact these forward-looking statements can be found in the Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Form 10-Q filed with the SEC on April 25, 2011.  A copy of this form can be found at the Investor Relations section of Express Scripts' web site at http://www.express-scripts.com.

We do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Express Scripts, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. ALS TDI Completes Gene Expression Profile of Lou Gehrigs Disease in Mice
2. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
3. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
4. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
5. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
6. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
7. Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
8. International Medical Corps Matched with Top 25 American Express Members Project, Saving the Lives of Malnourished Children
9. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
10. SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery
11. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013   Nektar Therapeutics (Nasdaq: NKTR ... liability (HAL) study for NKTR-181, a first-in-class, opioid ... brain.  This slow rate of entry is designed to reduce ... addiction to current opioid analgesics. 1 In the study ... to placebo in "drug liking" and "feeling high" scores and ...
(Date:6/19/2013)... Calif. , June 19, 2013 BD Biosciences, ... BDX ), a leading global medical technology company, today ... Analyzer , the latest in its line of high-performance research ... Analyzer delivers high-performance multicolor analysis with the most compact footprint ... 73.7 cm) and a height of 30" (76.2 cm). Recognizing ...
(Date:6/19/2013)... ZIONA, Israel , June ... announced that results from a phase I study in ... in advanced Parkinson,s patients, of ND0612, were presented at ... Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula ... delivery patch that would maintain constant levodopa plasma concentrations. ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
... ARBOR, Mich., Nov. 11, 2011 Adeona ... developer of innovative medicines for serious central nervous system ... estriol), will be utilized in a new Phase II ... cognitive dysfunction observed in female multiple sclerosis (MS) patients. ...
... 11, 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ... Officer, will be presenting at the Lazard Capital Markets 8th ... New York City. Mr. Bentsur,s presentation is scheduled to take ... A live audio webcast of Mr. Bentsur,s presentation ...
Cached Medicine Technology:Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 2Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 3Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 4Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 5Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2
(Date:6/19/2013)... 2013 Researchers from the Icahn ... new studies at ENDO 2013, The Endocrine Society’s ... in San Francisco.     , Mount Sinai researchers showed new ... of prostastic acid phosphatase (PAP) in Prostate Cancer (PCa) ... thyroid gland; revealed the prevalence of primary aldosteronism (PA) ...
(Date:6/19/2013)... TN (PRWEB) June 19, 2013 ... appointment of Dr. John Baxter to Vice President, Health ... serves as Director, Mental Health Services for CCA. ... is an honor and great privilege to lead CCA's ... the unique opportunity to serve society and our partners ...
(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... Citi Bike has come to New York City in a ... know for sure how many patients will choose to take advantage ... option. In fact, he’s happy about anything that might help ... more convenient for them to visit his office at 133 East ... Medicine at Back and Body Medical and an experienced NYC ...
(Date:6/19/2013)... emergency medicine and trauma surgery have had a ... days immediately after major injuries, including burns. ... injuries now are at greatest risk from infections ... as sepsis or from inflammation-induced multiorgan failure. ... Hospital (MGH) investigators that measures the movement of ...
Breaking Medicine News(10 mins):Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 3Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 4Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 5Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 6Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 7Health News:CCA Names Dr. John Baxter Vice President, Health Services 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3Health News:Restoring appropriate movement to immune cells may save seriously burned patients 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 3
... WASHINGTON, June 18 The American School,Health Association, ... National School Boards Association today joined together to ... 1108, the Family Smoking Prevention,and Tobacco Control Act, ... the,tobacco industry., These three associations, each formed ...
... (NYSE: HLS ) announced today that its Board ... per share on its 6.5%,Series A Convertible Perpetual Preferred ... on July 1, 2008., About HealthSouth, HealthSouth ... in 26 states across the country and in,Puerto Rico, ...
... But experts also express concern about psoriasis drug,s possible ... label needs strengthening , , WEDNESDAY, June 18 (HealthDay ... panel recommended Wednesday that the psoriasis drug Enbrel be ... of the skin disease. , The outside medical experts, ...
... light on the mechanism causing animals to develop the ... from their embryonic precursors, called somites. The number of ... across species. By comparing the developing embryos of zebrafish, ... understanding of how an organism regulates the number of ...
... Include More Components to Fully Measure Quality, ... (AHCA) today commended the Centers for Medicare & ... home care through,the newly introduced "five-star" rating system, ... quality index, any system that relies heavily,on survey ...
... second state-of-the-art CCRC across from its,Plantation Estates community ... ACTS Retirement-Life,Communities has signed a purchase agreement ... of Fullwood Lane and South Trade Street in,Matthews, ... independent,living apartments and single family homes with additional ...
Cached Medicine News:Health News:Major Associations Band Together to Urge Congressional Action on Tobacco Legislation 2Health News:HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock 2Health News:FDA Panel Recommends Enbrel for Pediatric Patients 2Health News:FDA Panel Recommends Enbrel for Pediatric Patients 3Health News:Pourquié Lab uncovers mechanism contributing to appropriate formation of the spine 2Health News:AHCA Emphasizes Quality Improvement in America's Nursing Homes 2Health News:ACTS Retirement-Life Communities Signs Land Purchase Agreement on 48-Acre Site in Matthews, North Carolina 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Inquire...
Medicine Products: